Background: Patients with well-differentiated and/or dedifferentiated liposarcoma (WD/DD LPS)
have few treatment options. The MDM2 gene encodes an E3 ubiquitin ligase that targets the p53 tumor suppressor for degradation;
it is amplified in WD/DD LPS and is a diagnostic hallmark. Milademetan (DS-3032b,
RAIN-32) is an oral MDM2 inhibitor with demonstrated preclinical antitumor activity.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2020 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
